Christopher Blakeley

418 total citations
15 papers, 210 citations indexed

About

Christopher Blakeley is a scholar working on Oncology, Genetics and Reproductive Medicine. According to data from OpenAlex, Christopher Blakeley has authored 15 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 14 papers in Genetics and 10 papers in Reproductive Medicine. Recurrent topics in Christopher Blakeley's work include BRCA gene mutations in cancer (11 papers), PARP inhibition in cancer therapy (11 papers) and Ovarian cancer diagnosis and treatment (10 papers). Christopher Blakeley is often cited by papers focused on BRCA gene mutations in cancer (11 papers), PARP inhibition in cancer therapy (11 papers) and Ovarian cancer diagnosis and treatment (10 papers). Christopher Blakeley collaborates with scholars based in Spain, United Kingdom and Italy. Christopher Blakeley's co-authors include Nicoletta Colombo, Giovanni Scambia, Andrés Poveda, Radosław Mądry, Sandro Pignata, Philippe Huot-Marchand, Kristina Lindemann, James V. Fiorica, Andrew R. Green and Rosalind Glasspool and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Christopher Blakeley

13 papers receiving 206 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Blakeley Spain 8 166 113 112 54 22 15 210
Ulla Peen Denmark 5 188 1.1× 29 0.3× 151 1.3× 70 1.3× 37 1.7× 8 237
Mansoor R. Mirza Denmark 5 143 0.9× 19 0.2× 79 0.7× 34 0.6× 18 0.8× 10 168
Lise M. van Wijk Netherlands 4 112 0.7× 37 0.3× 96 0.9× 98 1.8× 8 0.4× 5 192
Francisca Reyes Turcu United States 2 88 0.5× 19 0.2× 31 0.3× 72 1.3× 23 1.0× 2 140
Maria P. Intermaggio United States 3 46 0.3× 60 0.5× 30 0.3× 52 1.0× 10 0.5× 3 119
Christine Rappaport Austria 8 39 0.2× 93 0.8× 35 0.3× 66 1.2× 7 0.3× 14 157
Gregory Ulinski Mexico 3 40 0.2× 86 0.8× 132 1.2× 77 1.4× 30 1.4× 5 219
Ramūnas Janavičius Lithuania 9 73 0.4× 200 1.8× 53 0.5× 133 2.5× 3 0.1× 13 295
Stephanie L. Stenzel United States 3 90 0.5× 17 0.2× 8 0.1× 91 1.7× 9 0.4× 3 153
Satoko Uno Japan 4 16 0.1× 37 0.3× 141 1.3× 51 0.9× 97 4.4× 7 220

Countries citing papers authored by Christopher Blakeley

Since Specialization
Citations

This map shows the geographic impact of Christopher Blakeley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Blakeley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Blakeley more than expected).

Fields of papers citing papers by Christopher Blakeley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Blakeley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Blakeley. The network helps show where Christopher Blakeley may publish in the future.

Co-authorship network of co-authors of Christopher Blakeley

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Blakeley. A scholar is included among the top collaborators of Christopher Blakeley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Blakeley. Christopher Blakeley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Poveda, Andrés, Stéphanie Lheureux, Nicoletta Colombo, et al.. (2022). Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecologic Oncology. 164(3). 498–504. 29 indexed citations
3.
Pujade-Lauraine, Éric, Frédèric Selle, Giovanni Scambia, et al.. (2021). LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial. Annals of Oncology. 32. S1308–S1309. 42 indexed citations
4.
5.
Poveda, Andrés, Stéphanie Lheureux, Nicoletta Colombo, et al.. (2021). Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.. Journal of Clinical Oncology. 39(15_suppl). 5545–5545. 2 indexed citations
6.
7.
Poveda, Andrés, Stéphanie Lheureux, Nicoletta Colombo, et al.. (2020). Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.. Journal of Clinical Oncology. 38(15_suppl). 6057–6057. 7 indexed citations
8.
Waller, Cornelius F., Eduardo J. Pennella, Christopher Blakeley, et al.. (2019). Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Annals of Hematology. 98(5). 1217–1224. 14 indexed citations
9.
Poveda, Andrés, Richard Davidson, Christopher Blakeley, & Alvin Milner. (2019). Olaparib Maintenance Monotherapy in Platinum-Sensitive, Relapsed Ovarian Cancer Without Germline BRCA Mutations: OPINION Phase IIIb Study Design. Future Oncology. 15(32). 3651–3663. 11 indexed citations
10.
11.
Colombo, Nicoletta, Gloria S. Huang, Giovanni Scambia, et al.. (2018). Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. Journal of Clinical Oncology. 36(13). 1300–1307. 68 indexed citations
12.
Pujade-Lauraine, Éric, Nicoletta Colombo, Rosalind Glasspool, et al.. (2017). OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer. Annals of Oncology. 28. v351–v352. 13 indexed citations
13.
Waller, Cornelius F., Christopher Blakeley, Eduardo J. Pennella, et al.. (2017). Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta ® in the prophylactic treatment of chemotherapy-induced neutropenia. European Journal of Cancer. 72. S42–S42. 1 indexed citations
14.
Waller, Cornelius F., Christopher Blakeley, Eduardo J. Pennella, et al.. (2016). Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta® in the prophylaxis of chemotherapy-induced neutropenia. Annals of Oncology. 27. vi497–vi497. 4 indexed citations
15.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulla Peen Breakdown of academic impact, for papers by Mansoor R. Mirza Breakdown of academic impact, for papers by Lise M. van Wijk Breakdown of academic impact, for papers by Francisca Reyes Turcu Breakdown of academic impact, for papers by Maria P. Intermaggio Breakdown of academic impact, for papers by Christine Rappaport Breakdown of academic impact, for papers by Gregory Ulinski Breakdown of academic impact, for papers by Ramūnas Janavičius Breakdown of academic impact, for papers by Stephanie L. Stenzel Breakdown of academic impact, for papers by Satoko Uno
Rankless by CCL
2026